Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis
- 916 Downloads
Desmopressin 120 μg oral lyophilisate and 200 μg tablet are considered bioequivalent, based on extrapolation of studies in a limited number of adults and on one dose-finding study of desmopressin oral lyophilisate in children. However, no comparative pharmacokinetic study in children was executed confirming this statement. No data are available on the influence of food intake on the bioavailability of desmopressin tablet in a pediatric setting, although studies in adults have documented that food intake results in a significantly lower desmopressin plasma concentration. In this study, we analyzed plasma concentrations of desmopressin oral lyophilisate and tablet with concomitant food intake. Twenty-three children with monosymptomatic nocturnal enuresis (mean age, 12.7 years) were recruited. Two tests were performed on two separate days in identical conditions with a standardized food and fluid intake. Desmopressin was administered as desmopressin tablet or desmopressin oral lyophilisate immediately after a meal. Desmopressin plasma concentration was measured at 1 h, 2 h, and 6 h postdosing. No significant difference in plasma concentration of 120 μg desmopressin oral lyophilisate and 200 μg tablet was demonstrated, even with concomitant food intake. A significant difference in variability was found, identifying a smaller variance for desmopressin oral lyophilisate plasma concentrations at all time points. This study demonstrates comparable plasma levels for desmopressin oral lyophilisate, despite the lower dose. The dosage for desmopressin oral lyophilisate is more predictable due to the significantly smaller variance. Therefore, desmopressin oral lyophilisate seems more suitable, especially in the younger age group for which time interval between dinner and drug administration is limited.
KeywordsPharmacokinetics Desmopressin Monosymptomatic nocturnal enuresis Children
European Medicines Agency
International Conference on Harmonization
Liquid chromatography coupled with tandem mass spectrometry
Pediatric investigational plan
Pediatric use marketing authorization
This study was investigator-driven and was in part supported by an unrestricted grant from Ferring International. Pauline De Bruyne has received an independant grant for Strategic Basic Research of the Agency for Innovation by Science and Technology in Flanders (IWT).
- 1.(EMA), E. M. A. (2000). Note for guidance on the investigation of bioavailability and bioequivalence Google Scholar
- 2.Agency, E. M. (2006). REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 december 2006. Retrieved January 29, 2013, from http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 29 Jan 2013
- 11.Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, Djurhuus JC (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 176(1):314–324PubMedCrossRefGoogle Scholar
- 13.Osterberg O, Balchen T, Riis A, Senderovitz T (2006) Pharmacokinetics of desmopressin in children and adults using a new oral lyophilisate. Arch Dis Child 91:A31–A34Google Scholar
- 19.van Kerrebroeck PN, Norgaard JP (2009) Desmopressin for the treatment of primary nocturnal enuresis. Pediatr Heal 3(4):317–327Google Scholar